Citation Impact
Citing Papers
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
2017
A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
2015
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
2015
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
The molecular hallmarks of epigenetic control
2016 Standout
Talaporfin sodium
2009
Inflammation and cancer: advances and new agents
2015
Precision therapy for lymphoma—current state and future directions
2014
Natural products: A continuing source of novel drug leads
2013 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
2018 StandoutNobel
Macrophages in immunoregulation and therapeutics
2023 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Cancer stem cells revisited
2017 Standout
Relapsed childhood acute lymphoblastic leukaemia
2013
Delivery technologies for cancer immunotherapy
2019 Standout
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
2014
A chemical probe toolbox for dissecting the cancer epigenome
2017
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Antibody–drug conjugates: targeted drug delivery for cancer
2010
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Epigenetic protein families: a new frontier for drug discovery
2012
Antibody–drug conjugates: current status and future directions
2013
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
2013
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
2016
Photodynamic therapy of cancer: An update
2011 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
2012 StandoutNobel
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
2017
New developments for antibody-drug conjugate-based therapeutic approaches
2016
Chemoprotective effect of thymol against genotoxicity induced by bleomycin in human lymphocytes
2015
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development
2017 Standout
Molecular pathogenesis of mantle cell lymphoma
2012
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
2013 Standout
Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management
2018
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
2015
New and emerging HDAC inhibitors for cancer treatment
2014
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015
Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
2012
Tremelimumab: A Review of Development to Date in Solid Tumors
2013
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Combination therapy in combating cancer
2017 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
2013
Oxime Ligation on the Surface of Mesoporous Silica Nanoparticles
2015 StandoutNobel
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation
2015
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
2015
Linkers Having a Crucial Role in Antibody–Drug Conjugates
2016
PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
2013
Works of Amanda Copeland being referenced
Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
2009
Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
2011
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
2016
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
2011
Histone deacetylase inhibitors in lymphoma
2010
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study
2011
Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
2013
Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).
2009
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
2012
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
2012
Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.
2010